Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_04959 |
| Species: | Homo sapiens |
| Position : | chr4:150577837-150588968 |
| Year: | 2026 |
| Title: | Targeting super-enhancer-driven MAB21L2 suppresses neuroblastoma growth and migration. |
| Genome Build: | hg38 |
| Enhancer Type: | Super-enhancer |
| Condition: | Disease |
| Disease Name: | neuroblastoma |
| PMID: | 41651436 |
| MONDO: | MONDO:0005072 |
| Tissue: | bone marrow |
| Tissue Ontology ID: | UBERON:0002371 |
| Cell Source: | SK-N-BE(2) |
| CVCL ID: | CVCL_0528 |
| Cell Type: | neuroblastoma cell |
| Experiment Type: | Super-enhancer identification; Functional perturbation assay; Transcriptomic analysis; Tumor growth and migration assay |
| High Throughput Method: | RNA-seq; epigenomic super-enhancer profiling |
| Low Throughput Method: | MAB21L2 knockdown; in vitro proliferation assay; migration assay; in vivo xenograft tumor-growth assay |
| Target gene : | MAB21L2 |
| TF name : | NA |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|